Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
Intricon Corporation has been recognized by MedTech Outlook Magazine as the exclusive recipient of “Top 10 Patient Monitoring Devices Providers - 2022,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the MedTech Outlook research and editorial team based on insights from an interview with Dave Liebl, Chief Commercial and Technology Officer.
Dave Liebl, Chief Commercial and Technology Officer
Company
Intricon Corporation
Management
Dave Liebl, Chief Commercial and Technology Officer
Description
For more than 45 years, Intricon has been improving people’s lives with sensor-enabled micromedical devices. Focused exclusively on medical technology, Intricon is a contract development and manufacturing partner to industry-leading medical device companies around the world. Intricon applies a unique combination of microelectronic and regulatory expertise to bring some of the world’s smallest, smartest devices to life. Companies partner with Intricon to optimize supply chains and cost effectively scale production of their current and next generation micromedical devices.
Sito Web:
mythras.it
Amministratore:
Roberto Livio Mastronardi, co-fondatore
Descrizione:
Mythras è un team di tecnici specializzati nell'assistenza tecnica su strumentazione IVD, esperti nell'aiutare i responsabili di laboratorio a garantire la precisione, l'accuratezza e la conformità dei loro strumenti. È la scelta ideale per numerosi clienti e distributori, al servizio delle loro complesse esigenze di assistenza tecnica e ricondizionamento della strumentazione IVD.
Citazione:
“Siamo certificati ISO 9001:2015 per l'assistenza tecnica e il ricondizionamento della strumentazione analitica IVD.”
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
